BioNexus Gene Lab (BGLC) Equity Ratio (2018 - 2026)

BioNexus Gene Lab's Equity Ratio history runs 9 years deep, the most recent figure standing at 0.9 for Q1 2026.

• In Q1 2026, Equity Ratio rose 9.2% year-over-year to 0.9; the TTM figure through Mar 2026 stood at 0.9 (up 9.2% YoY), while the FY2025 annual figure was 0.93, up 16.72% from the prior year.
• Equity Ratio came in at 0.9 for Q1 2026 at BioNexus Gene Lab, down from 0.93 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.93 in Q4 2025 to a low of 0.71 in Q2 2023.
• A 5-year average of 0.82 and a median of 0.82 in 2025 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio decreased 13.15% in 2023 and gained 21.04% in 2024, its largest moves.
• BioNexus Gene Lab's Equity Ratio stood at 0.76 in 2022, then increased by 11.1% to 0.85 in 2023, then slipped by 5.85% to 0.8 in 2024, then advanced by 16.72% to 0.93 in 2025, then fell by 3.85% to 0.9 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.9, 0.93, and 0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison